COVID-19 Drug Treatment in China

Linzi Fan; Shuang Jiang; Xinrong Yang; Zhibin Wang; Chunjuan Yang

doi:10.1007/s40495-020-00218-5

COVID-19 Drug Treatment in China

Curr Pharmacol Rep. 2020;6(4):146-154. doi: 10.1007/s40495-020-00218-5. Epub 2020 Sep 7.

Authors

Linzi Fan¹, Shuang Jiang¹, Xinrong Yang¹, Zhibin Wang², Chunjuan Yang¹

Affiliations

¹ Department of Pharmaceutical Analysis and Analytical Chemistry, College of Pharmacy, Harbin Medical University, No. 157 Baojian Road, Nangang District, Harbin, 150081 Heilongjiang People's Republic of China.
² Key Laboratory of Chinese Materia Medica (Ministry of Education), Heilongjiang University of Chinese Medicine, Harbin, 150040 Heilongjiang China.

Abstract

Purpose of review: An unprecedented outbreak of the novel coronavirus in China (COVID-19) occurred in December 2019, and then engulfed the entire world, presenting a significant and urgent threat to global health. Many research institutes have been involved in the development of drugs and vaccines against COVID-19.

Recent findings: At present, the strategy of new use of old drugs is mainly used to screen candidate drugs against the novel coronavirus (later termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) and inhibit excessive immune response. Related research has made great progress.

Summary: In this review, we summarize the drugs used for COVID-19 treatment in China based on the emerging basic and clinical data. It is hoped that this review will be useful to provide guidance for the prevention, treatment, and control of COVID-19.

Keywords: COVID-19; Medical treatment; New drug research and development; SARS-CoV-2.

Publication types

Review